Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial (GlobeNewswire) - Aug 19, 2021 - "Plus Therapeutics...presented data from a preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of leptomeningeal metastases (LM), and presented plans for a Phase 1 clinical trial of 186RNL also in LM. The data and upcoming trial plans were presented in two electronic posters (ePosters) at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), being held virtually August 19-20, 2021...Kaplan-Meier plot showed a statistically significant difference in overall survival with the 186RNL-treated animals outliving the controls (p=0.0377)...In addition, the Company presented trial design plans for its upcoming Phase 1 clinical trial as part of an ePoster entitled...The starting dose of 186RNL will be 6.6 mCi in a volume of 5 mL followed by an expansion at the maximum tolerated dose to determine efficacy."
Clinical protocol • Preclinical • CNS Tumor • Oncology
|